Accepting all cookies will ensure the best experience on our website, including content personalization and social media features. Accepting only necessary cookies will allow minimal cookie usage while you browse, but some parts of the website might not display correctly. To find out more, check our Privacy Policy.
15th EGA Regulatory and Scientific Affairs Conference had offered an update on recent regulatory developments, and answered the following answers:
- Looking to the future- EMA/HMA Strategy 2020 Work Plan- how will it impact the regulatory environment for pharmaceuticals?
- Tackling effects of the globalisation of pharmaceutical operations – challenges, opportunities and priorities
- Maintenance of medicinal products: is there a better way of handling it in practice?
- Borderline medicinal products - Do on-going changes to medical devices, food supplement legislations impact my products?
- How does the ICH 3QD guideline on elemental impurities affect my products?
- ISO IDMP is around the corner: are we set and ready to start with implementation?
Key Takeaways
- Regulatory implications of various changes in the legal and operational environment
- Electronic submission environment
Photos
Romuald Braun and Bernard Ferber at Amplexor's booth